HPLC Method for Analysis of Fitusiran on OligoMG Column

Separation type: Bridge Ion Separation Technology, or BIST™ by SIELC Technologies

HPLC Method for Analysis Fitusiran on OligoMg Column by SIELC Technologies

HPLC Method for Analyzing Fitusiran on OligoMg Column by SIELC Technologies

Fitusiran is a relatively new therapeutic agent developed for the treatment of hemophilia A and B, including in patients with or without inhibitors.

Using SIELC’s newly introduced BIST™ method, this oligonucleotide can be retained on a OligoMg column. Using this new and unique analysis method, oligonucleotide can be separated, retained, and detected at 260 nm.

Please read more on oligonucleotides analysis by HPLC in our June 2024 newsletter.

Condition

ColumnOligoMg, 4.6 x 100 mm, 3 µm, 100 A
Mobile PhaseGradient MeCN 60-10%, 10 min
Buffernone
Flow Rate1.0 ml/min
DetectionUV 260 nm

Description

Class of CompoundsDrug, RNA
Analyzing CompoundsFitusiran

Application Column

HPLC Column for Oligonucleotides

OligoMg

Column Diameter: 4.6 mm
Column Length: 100 mm
Particle Size: 3 µm
Pore Size: 100 A

Add to cart
Application Analytes:
Fitusiran

Application Detection:
UV Detection
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.